Sat.Mar 20, 2021 - Fri.Mar 26, 2021

article thumbnail

Life-sciences pros believe in potential of AI, blockchain: survey

Outsourcing Pharma

A survey by the Pistoia Alliance indicates most professionals believe the tech can accelerate R&D, but companies are stymied by a skills gap and data bias.

145
145
article thumbnail

Gamification for patient care, medical education, and virtual engagement

pharmaphorum

“Gamification” – adding game-like elements into non-game or real-world settings – has become a popular concept in the pharmaceutical, healthcare, and event industries, especially as virtual engagement becomes more common during COVID-19. However, it is proving more than a mere buzzword. With diverse applications and approaches, it is quickly becoming a promising tool for patient adherence, chronic disease management, preventive medicine, rehabilitation, and paediatric care, as well as for medica

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

22 ibuprofen alternative drugs you must know

Druggist

Ibuprofen is one of the most common drugs purchased over the counter in the UK. Ibuprofen prescribing decreased significantly in recent years due to the NHS strategy to minimise issuing of medicines that are available over the counter. In recent months, ibuprofen’s price went up significantly, with many shops and pharmacies being out of stock of ‘cheap’ ibuprofen.

article thumbnail

Digital Tools at the Center of Healthcare Digitalization

Pharma Marketing Network

Innovation During COVID-19 Fact Sheet. We compiled a fact sheet on innovations in digital publishing that sparked due to the pandemic and have since been soaring. . Get your complimentary copy of "The Publishing Industry: The Soar of Innovation During COVID-19 Fact Sheet". Name *. First. Last. Company Email *. Lead Source * Web Active Prospecting Sales Ad-Label Advertising - Offline Advertising - Online Advertising - Online - FocalPoint Advertising - Online - Mobile Advertising - Online - Trend

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

MedVector introduces patient enrollment expansion solution

Outsourcing Pharma

The companyâs Prime-Control Technology is designed to help study teams expand their subject enrollment beyond the reach of their clinical trial sites.

98
article thumbnail

Novartis’ radioligand therapy meets phase 3 prostate cancer trial target

pharmaphorum

Novartis’ radioligand therapy Lu-PSMA-617 has met its target in prostate cancer, as its $2.1 billion acquisition of specialist pharma Endocyte looks to have been justified. . The big Swiss pharma added this drug to its pipeline after it swooped for Endocyte and so far it looks like a good piece of business, with potential blockbuster sales predicted for the drug if it makes it to market.

More Trending

article thumbnail

How to Achieve and Maintain a Nice Smile

Pharma Mirror

One of the best gifts you can give to another person is a beautiful smile. Though it costs you nothing, it goes a long way in adding to others and you. It typically has a favourable effect on others, attracts people to you, and makes you approachable and likeable. A smile is very important. It is a part of your dressing and personality. Without a smile, you are incomplete, no matter how expensively and gorgeously dressed you are.

52
article thumbnail

Cancer research benefits from harnessing real-world data

Outsourcing Pharma

A leader from oncologist-founded trial tech specialists COTA shares how advanced data analysis can benefit cancer researchers and patients alike.

98
article thumbnail

Boris Johnson slammed for saying “greed” is behind UK vaccine success

pharmaphorum

Boris Johnson’s sense of humour seems to have got him into trouble again, at the most delicate of times. The Prime Minister reportedly told Conservative backbench MPs on a Zoom call that “capitalism” and “greed” was behind the success of the UK’s COVID-19 vaccination programme, before backtracking after realising he had made a blunder and telling attendees to forget the comments.

Vaccines 124
article thumbnail

FDA nod for Kiniksa’s Arcalyst in recurrent pericarditis

Pharma Times

Recurrent pericarditis is an autoinflammatory cardiovascular disease

FDA 52
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

The Momentum of Decentralized Clinical Trials: An Interview with R’Kes Starling

McCreadie Group

March 2021 | Jennifer Drabing, Senior Marketing Communications Manager McCreadie Group is proud to work with Reveles Clinical Services and privileged to sit down with its CEO and founder, R’Kes Starling, to discuss decentralized clinical trials. This blog, the first part of the interview series with R’Kes, focuses on the future of virtual trails, the.

article thumbnail

Online health communities connect patients, trial teams

Outsourcing Pharma

Health Union offers patients dealing with a range of conditions ways to connect with valuable information, research opportunities and each other online.

72
article thumbnail

The Brexit deal; shot in the arm or kick in the teeth for the pharma sector?

pharmaphorum

The UK Government and EU Commission trumpeted their Brexit trade deal, struck at the end of December, as ‘comprehensive’, the ‘biggest yet’ But a closer inspection of the EU-UK Trade and Cooperation Agreement (TCA) renders these statements largely illusory for the pharma sector. While pharma companies grapple with the effects of Brexit, there are undoubtedly a number of ways that the TCA benefits the sector, while leaving significant issues unanswered.

article thumbnail

Two-month long CPhI Japan Connect to meet demand for pharma partnering in Japan

Pharma Mirror

The Japanese pharmaceutical market is preparing for renewed international growth and partnering. In response, CPhI Japan has opened a two-month long virtual event to meet demand from international pharma. Informa introduced CPhI Japan Connect – a new virtual platform for global professionals looking to grow pharma business in Japan – specifically to help its international audiences continue conversations, identify leads, and build new partnerships while international travel remains restricted.

52
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Researchers identify new genetic clues for ‘silent’ strokes

Pharma Times

British Heart Foundation-funded researchers hope findings can aid the development of new treatments

50
article thumbnail

IQVIA expands reach of its decentralized trial solutions

Outsourcing Pharma

The company reports that its patient-centric virtual study technology currently is in use in more than 60 ongoing trials in over 40 different countries.

72
article thumbnail

AI drug discovery player 1910 Genetics debuts with $26m war chest

pharmaphorum

There’s a new kid on the block among companies using artificial intelligence in drug discovery, after 1910 Genetics launched today with $26 million in financing. The Cambridge, Massachusetts-based startup claims it is the only biotech launched so far that will use AI to design both small-molecule drugs and protein therapeutics, coupled with automated biological testing to speed up drug development and reduce costs.

article thumbnail

Medications For Akathisia

Med Ed 101

Akathisia is one of the most common symptoms associated with extrapyramidal symptoms (EPS) due to antipsychotics. There are a few different medications that we can use for the management of akathisia. Here’s a good summary of akathisia. Prior to even considering medications for akathisia management, we need to remember that some antipsychotics carry a higher […].

40
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

EMA accepts Astellas/Seagen’s enfortumab vedotin for review

Pharma Times

Marketing authorisation application is seeking approval for advanced urothelial cancer

49
article thumbnail

Collecting patient data challenging in evolving trial landscape

Outsourcing Pharma

Two experts from CRO Phastar talk about how trial professionals face new, ever-changing challenges regarding collecting and disseminating patient data.

59
article thumbnail

Solving the “information challenge” of rare disease diagnosis

pharmaphorum

Getting a diagnosis is often the biggest challenge facing a rare disease patient in the UK. We take a look at efforts from charities, the government and digital innovators to boost awareness of rare conditions among GPs and make the clinical pathway smoother for patients. There are more than 150,000 people living with a rare neurological condition in the UK, which taken together means that these conditions aren’t actually that rare at all – and that’s just for one slice of the wider rare disease

105
105
article thumbnail

Cerelle vs Cerazette: Are they really the same?

Druggist

Cerelle and Cerazette are two brands of daily progestogen-only pill (POP), also known as mini-pill. In recent years prescribing of Cerazette in NHS decreased, in place of other brands, including Cerelle. Today I will discuss the reasons for this change and review different aspects of Cerelle vs Cerazette use. . Summary of the post: Cerelle vs Cerazette: are they the same?

article thumbnail

Cambridge start-up PhoreMost raises £33m to progress PLK1 programme

Pharma Times

Lead ‘Allosteric PLK1’ asset will initially target brain cancer

49
article thumbnail

Amgen v Sanofi ruling: It is time to kiss goodbye to broad, functional patent claims for antibodies

Outsourcing Pharma

A US courtâs recent decision to find in favor of Sanofi and invalidate Amgen's broad antibody patent claims has biotech manufacturers concerned about how to preserve their IP.

56
article thumbnail

Doubts emerge over AZ’s ‘outdated’ US vaccine trial data

pharmaphorum

AstraZeneca has been rebuked by a US health authority after a trial monitoring board said data published from a large study of its COVID-19 vaccine may be out of date and may not give a representative view of its efficacy. The company’s share price ticked down after the statement on Monday from the US National Institute for Allergy and Infectious Diseases (NIAID).

article thumbnail

Fewer New Drugs but Affordable Access for Existing Ones: The Big Elephant in the Room

Policy Prescription

Would you vote for legislation to lower drug prices that would lead to a five percent reduction in pharmaceutical innovation — yet simultaneously create a health system in which all Americans could afford the prescription drugs they need? That’s compared to the one we have now where a quarter of Americans struggle with drug prices. I would vote for it.

article thumbnail

Relugolix shows potential long-term benefit in women with uterine fibroids

Pharma Times

Study compared women who continued on relugolix combination therapy with women who discontinued treatment

49
article thumbnail

Medable advisory council works to amplify patient voice, inclusivity

Outsourcing Pharma

The companyâs Patient Advisory Council brings together a range of people and perspectives to help ensure increased diversity, inclusivity and engagement.

52
article thumbnail

Roche stops dosing in trial of Huntington’s disease hopeful tominersen

pharmaphorum

Roche has stopped dosing in a phase 3 trial of tominersen, a potential Huntington’s disease (HD) drug developed with Ionis, after a pre-planned review by independent experts. . The companies had been working on tominersen since December 2017, when Roche licensed it in from Ionis. There were high expectations for tominersen, which the companies hoped would be the first drug to treat the underlying cause of the disease, which leads to devastating neurological degeneration.

article thumbnail

Belgium’s eTheRNA gets EU grant to develop mRNA cancer vaccines

pharmaphorum

Belgian immunotherapy firm eTheRNA has received a €6.9 million grant from the European Commission to accelerate clinical development of mRNA therapies for hard-to-treat cancers. mRNA therapies have been in the spotlight since BioNTech and Pfizer used the technology to create a vaccine against COVID-19 last year. But it was cancer that the German biotech originally targeted with the technology, which is capable of converting cells into “drug factories” to fight a range of diseases. eTheRNA is als

article thumbnail

Aura raises $80m to develop its virus-like cancer drugs

pharmaphorum

US biotech Aura Biosciences has closed an oversubscribed financing, raising $80 million to help take its lead virus-like drug conjugate (VDC) for a cancer that affects the eye into late-stage development. The Cambridge, Massachusetts-based company is currently testing belzupacap sarotalocan (AU-011) in a phase 2 trial involving patients with choroidal melanoma, a tumour that develops in the back of the eye that can cause vision loss and is almost invariably fatal if it spreads to other parts of

FDA 72
article thumbnail

MHRA launches patient involvement pilot for drug applications

pharmaphorum

The UK drugs regulator is now asking that all applications for new medicines or indications detail the efforts made to involve patients in the drug development process. . The voluntary scheme by the Medicines and Healthcare products Regulatory Agency (MHRA) aims to inject a dose of “patient centricity” into medicines development – something that has been talked about by the pharma industry for years but arguably hasn’t yet become an intrinsic part of the process.

article thumbnail

Another UK hospital trials clinical comms platform Bleepa

pharmaphorum

UK medical imaging firm Feedback has continued its expansion of its digital communication platform Bleepa with a one-year contract with a large UK hospital. The UK’s National Health Service is trying to phase out use of outmoded technologies such as pagers and faxes. But there are concerns that clinical teams are resorting to commercial apps such as Whatsapp, which have not been cleared by regulators for use in clinical settings.